JP2014509861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509861A5 JP2014509861A5 JP2013558466A JP2013558466A JP2014509861A5 JP 2014509861 A5 JP2014509861 A5 JP 2014509861A5 JP 2013558466 A JP2013558466 A JP 2013558466A JP 2013558466 A JP2013558466 A JP 2013558466A JP 2014509861 A5 JP2014509861 A5 JP 2014509861A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 123
- 150000001413 amino acids Chemical class 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 239000012634 fragment Substances 0.000 claims 46
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 30
- 102000053826 human CD70 Human genes 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 13
- 102100025221 CD70 antigen Human genes 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 5
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 241000282560 Macaca mulatta Species 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 206010002921 Aortitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453390P | 2011-03-16 | 2011-03-16 | |
| US61/453,390 | 2011-03-16 | ||
| US201161503871P | 2011-07-01 | 2011-07-01 | |
| US61/503,871 | 2011-07-01 | ||
| PCT/EP2012/054733 WO2012123586A1 (en) | 2011-03-16 | 2012-03-16 | Antibodies to cd70 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016103443A Division JP6261651B2 (ja) | 2011-03-16 | 2016-05-24 | Ｃｄ７０に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509861A JP2014509861A (ja) | 2014-04-24 |
| JP2014509861A5 true JP2014509861A5 (https=) | 2015-04-30 |
| JP5982409B2 JP5982409B2 (ja) | 2016-09-07 |
Family
ID=45878935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558466A Active JP5982409B2 (ja) | 2011-03-16 | 2012-03-16 | Ｃｄ７０に対する抗体 |
| JP2016103443A Active JP6261651B2 (ja) | 2011-03-16 | 2016-05-24 | Ｃｄ７０に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016103443A Active JP6261651B2 (ja) | 2011-03-16 | 2016-05-24 | Ｃｄ７０に対する抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US9765148B2 (https=) |
| EP (1) | EP2686347B1 (https=) |
| JP (2) | JP5982409B2 (https=) |
| CN (1) | CN103596979B (https=) |
| AU (1) | AU2012228194B2 (https=) |
| BR (1) | BR112013021562B1 (https=) |
| CA (1) | CA2828753C (https=) |
| CY (1) | CY1120471T1 (https=) |
| DK (1) | DK2686347T3 (https=) |
| ES (1) | ES2670874T3 (https=) |
| HU (1) | HUE039849T2 (https=) |
| IL (1) | IL228001B (https=) |
| PL (1) | PL2686347T3 (https=) |
| PT (1) | PT2686347T (https=) |
| RU (1) | RU2604196C2 (https=) |
| SI (1) | SI2686347T1 (https=) |
| TR (1) | TR201807202T4 (https=) |
| WO (1) | WO2012123586A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08935B2 (ja) | 1991-03-15 | 1996-01-10 | 新日本製鐵株式会社 | 線材コイルの脱水素処理装置 |
| WO2009135181A2 (en) | 2008-05-02 | 2009-11-05 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP2686347B1 (en) | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| EP3508215A3 (en) * | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| WO2014176696A1 (en) * | 2013-04-30 | 2014-11-06 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
| AU2014317009A1 (en) * | 2013-09-05 | 2016-03-10 | Aduro Biotech Holdings, Europe B.V. | CD70-binding peptides and method, process and use relating thereto |
| US10391168B1 (en) * | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| KR102390359B1 (ko) * | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| US20180244792A1 (en) * | 2015-09-10 | 2018-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| GB2567613A (en) * | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| PE20210119A1 (es) | 2017-10-31 | 2021-01-19 | Staten Biotechnology B V | Anticuerpos anti-apoc3 y metodos de uso de estos |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| PE20210708A1 (es) * | 2018-02-01 | 2021-04-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| CN112020518A (zh) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| CA3119644A1 (en) | 2018-11-30 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| CA3166832A1 (en) * | 2020-01-08 | 2021-07-15 | Board Of Regents, The University Of Texas Systems | A method of engineering natural killer cells to target cd70-positive tumors |
| CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
| JP2023532197A (ja) * | 2020-06-30 | 2023-07-27 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ７０抗体及びその応用 |
| US20230266332A1 (en) | 2020-07-28 | 2023-08-24 | Inserm (Institut National De La Santè Et De La Recherch Médicale) | Methods and compositions for preventing and treating a cancer |
| EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| WO2022116952A1 (zh) | 2020-12-01 | 2022-06-09 | 苏州克睿基因生物科技有限公司 | 靶向cd70的抗原结合蛋白及其应用 |
| CN114685657B (zh) * | 2020-12-31 | 2024-08-16 | 康诺亚生物医药科技（成都）有限公司 | 一种功能增强型抗体阻断剂的开发及其应用 |
| CN115260303B (zh) * | 2021-05-31 | 2025-04-22 | 百奥赛图(北京)医药科技股份有限公司 | Cd70基因人源化非人动物的构建方法及应用 |
| CN116375865A (zh) * | 2021-06-17 | 2023-07-04 | 南京蓝盾生物科技有限公司 | 具有增强的adcp效应的抗cd70抗体及其应用 |
| CN113754769B (zh) | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd70的抗体及其制备和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| TWI871168B (zh) * | 2023-01-16 | 2025-01-21 | 大陸商上海華奧泰生物藥業股份有限公司 | 靶向cd70的抗體或結合cd70的抗原結合片段及其製備方法和應用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| EP1470247A2 (en) | 2001-11-05 | 2004-10-27 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
| ES2394018T3 (es) | 2001-11-27 | 2013-01-15 | Ucb Pharma S.A. | Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| JP2007525438A (ja) | 2003-03-24 | 2007-09-06 | ザイモジェネティクス， インコーポレイテッド | 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法 |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| AU2005299809B2 (en) | 2004-10-22 | 2010-12-02 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| JP5122441B2 (ja) * | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| EP1872124A4 (en) | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF |
| WO2007011856A2 (en) | 2005-07-15 | 2007-01-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for differential diagnosis of chronic lymphocytic leukemia |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| PT2099823E (pt) * | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| MX2009006277A (es) | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
| AR062123A1 (es) * | 2007-07-27 | 2008-10-15 | Inst Nac De Tecnologia Agropec | Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus |
| KR100807069B1 (ko) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | 암 치료용 의약 조성물 |
| US20100267626A1 (en) | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| US9120854B2 (en) * | 2008-04-11 | 2015-09-01 | Seattle Genetics, Inc. | Detection and treatment of pancreatic, ovarian and other cancers |
| US20110165620A1 (en) | 2008-05-28 | 2011-07-07 | Roland Romijn | Method for the production of proteins or protein fragments |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
| WO2010019921A2 (en) | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| CN102257003B (zh) * | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
| JP5748653B2 (ja) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法 |
| CN105037355B (zh) | 2009-08-10 | 2017-06-06 | 萨穆梅德有限公司 | Wnt信号传导途径的吲唑抑制剂及其治疗用途 |
| US20120178111A1 (en) | 2009-09-23 | 2012-07-12 | Diamandis Eleftherios P | Methods and compositions for the detection of lung cancers |
| UA105405C2 (ru) | 2009-11-19 | 2014-05-12 | Мерк Сероно С.А. | Гуманизированное антитело против человеческого il-22ra |
| KR101773216B1 (ko) | 2009-12-29 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ27 항체 |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
| EP2686347B1 (en) | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| MX353958B (es) | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| WO2013093508A2 (en) | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
| NZ629697A (en) | 2012-03-15 | 2017-01-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
| KR20140145148A (ko) | 2012-03-21 | 2014-12-22 | 에리테끄 파르마 | 급성 골수성 백혈병 치료를 위한 약제 |
| US9801851B2 (en) | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| EP2861590B1 (en) | 2012-06-15 | 2017-10-25 | Curegenix Inc. | Compound as wnt signaling inhibitor, composition, and use thereof |
| EP2977386A1 (en) | 2012-08-31 | 2016-01-27 | Argen-X Nv | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| CN106456749B (zh) | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3125645A1 (en) | 2015-07-31 | 2017-02-01 | Bleckmann GmbH & Co. KG | Flange assembly for securing a heating device to a fluid container |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| US20180244792A1 (en) | 2015-09-10 | 2018-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
-
2012
- 2012-03-16 EP EP12710486.7A patent/EP2686347B1/en active Active
- 2012-03-16 JP JP2013558466A patent/JP5982409B2/ja active Active
- 2012-03-16 WO PCT/EP2012/054733 patent/WO2012123586A1/en not_active Ceased
- 2012-03-16 AU AU2012228194A patent/AU2012228194B2/en active Active
- 2012-03-16 HU HUE12710486A patent/HUE039849T2/hu unknown
- 2012-03-16 SI SI201231335T patent/SI2686347T1/en unknown
- 2012-03-16 BR BR112013021562-3A patent/BR112013021562B1/pt active IP Right Grant
- 2012-03-16 CA CA2828753A patent/CA2828753C/en active Active
- 2012-03-16 PL PL12710486T patent/PL2686347T3/pl unknown
- 2012-03-16 US US14/005,113 patent/US9765148B2/en active Active
- 2012-03-16 ES ES12710486.7T patent/ES2670874T3/es active Active
- 2012-03-16 DK DK12710486.7T patent/DK2686347T3/en active
- 2012-03-16 RU RU2013146106/10A patent/RU2604196C2/ru active
- 2012-03-16 PT PT127104867T patent/PT2686347T/pt unknown
- 2012-03-16 TR TR2018/07202T patent/TR201807202T4/tr unknown
- 2012-03-16 CN CN201280013552.5A patent/CN103596979B/zh active Active
-
2013
- 2013-08-18 IL IL228001A patent/IL228001B/en active IP Right Grant
- 2013-11-06 US US14/073,462 patent/US8834882B2/en active Active
-
2014
- 2014-01-24 US US14/163,752 patent/US9765149B2/en active Active
-
2015
- 2015-02-19 US US14/626,038 patent/US11072665B2/en active Active
-
2016
- 2016-05-24 JP JP2016103443A patent/JP6261651B2/ja active Active
-
2018
- 2018-07-27 CY CY20181100783T patent/CY1120471T1/el unknown
-
2019
- 2019-02-18 US US16/278,522 patent/US11434298B2/en active Active
-
2022
- 2022-07-11 US US17/811,645 patent/US20230265201A1/en not_active Abandoned
-
2025
- 2025-08-06 US US19/292,687 patent/US20260042856A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509861A5 (https=) | ||
| RU2013146106A (ru) | Антитела против cd70 | |
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| KR102003754B1 (ko) | Pd-l1 항체와 이를 이용한 치료 및 진단 | |
| US20200377594A1 (en) | Humanized antibodies for cd3 | |
| IL312961A (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| JP2020501531A5 (https=) | ||
| RU2017121327A (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2016505556A5 (https=) | ||
| JP2018503380A5 (https=) | ||
| JP2018522541A5 (https=) | ||
| JP2017532037A5 (https=) | ||
| JP2014531201A5 (https=) | ||
| JP2014523408A5 (https=) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2012530496A5 (https=) | ||
| JP2016503067A5 (https=) | ||
| JP2019516392A5 (https=) | ||
| JP2023519962A5 (https=) | ||
| WO2013072523A4 (en) | Bi-specific antibodies for medical use | |
| AU2019258468B2 (en) | Antibody against TIM-3 and application thereof | |
| WO2023217227A1 (zh) | 喜树碱类衍生物及配体-药物偶联物 |